ReviewPediatric health, medicine and therapeutics2025
Neonatal Hyperbilirubinemia in Uganda: Mechanisms, Clinical Consequences, and Health-System Challenges.
Review in Pediatric health, medicine and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical outcomes and determinants of neonatal hyperbilirubinemia among NICU admissions: a retrospective study in Ethiopia.Scientific reports · 2026Article
- Evaluating the Impact of Phototherapy on Serum Bilirubin Levels and Clinical Outcomes in Neonates: A Single-Center Retrospective Study in a Resource-Limited Setting in Somalia.Pediatric health, medicine and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neonatal hyperbilirubinemia is a prevalent condition characterized by elevated serum bilirubin levels, affecting approximately 50% of term and 80% of preterm infants. While mild cases often resolve without intervention, severe hyperbilirubinemia can lead to life-threatening complications such as bilirubin-induced neurological dysfunction (BIND) and kernicterus, resulting in permanent brain damage, developmental delays, and hearing impairment. Materials and Methods: A literature review was conducted by searching PubMed, Google Scholar, and UpToDate for English-language articles published between January 2010 and March 2025 on neonatal hyperbilirubinemia. Inclusion criteria were studies on mechanisms, clinical outcomes, and interventions in low- and middle-income countries (LMICs), with a focus on Uganda. Exclusion criteria included case reports, non-English studies, and articles without primary data. Results: The condition arises from an imbalance between bilirubin production and elimination, influenced by immature liver function, increased red blood cell turnover, enhanced enterohepatic circulation, and genetic predisposition. In low-income countries such as Uganda, additional contributors include delayed postnatal care-seeking, limited availability of phototherapy units, and inadequate early screening programs. The low-income country has inappropriate early screening and poor treatment options, which further exacerbate the burden, contributing to preventable neonatal morbidity and mortality. Conclusion: Timely screening, improved access to phototherapy and exchange transfusion, and increased awareness among healthcare providers and caregivers are essential for reducing the impact of neonatal hyperbilirubinemia. By integrating biological mechanisms, clinical consequences, and health-system challenges into a single synthesis, this review provides novel, actionable insights for policy-makers and clinicians in Uganda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.